CD36: a key mediator of resistance to HER2 inhibitors in breast cancer

Abstract

Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy.

Keywords

• fasn
• fatp
• lapatinib
• lipid metabolism
• trastuzumab